Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China-Prevalent Form of NSCLC Responds to AstraZeneca Drug

publication date: Dec 6, 2016
AstraZeneca announced positive results from a Phase III trial of Tagrisso in patients with relapsed non-small cell lung cancer. Tagrisso is a third-gen oral epidermal growth factor receptor (EGFR) inhibitor that targets NSCLC with the T790M mutation. Although only 10%-15% of NSCLC patients in the west have the mutation, about 50% of cases in China and east Asia do. In the trial, Tagrisso raised the median time-to-progression to 10.1 months from 4.4 months. Tagrisso, which is available in the US as a second-line treatment, is under Fast-Track review in China. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital